Revefenacin (Inhalation)

Introduction Overview

Generic Name

revefenacin (inhalation)

Brand Name

Yupelri

Dosage Form

Inhalation solution for nebulization

Drug Class

Anticholinergic bronchodilators

Pharmacokinetics

Absorption:
Revefenacin is administered via nebulization, allowing direct delivery to the lungs. After inhalation, systemic absorption of revefenacin is minimal, thereby reducing systemic side effects. In clinical pharmacokinetic studies, peak plasma concentrations are typically achieved within 10 to 15 minutes post-dose. The inhaled route ensures rapid onset of action localized to the airway smooth muscle. Additionally, the inhaled administration avoids first-pass hepatic metabolism, leading to enhanced local pulmonary bioavailability. Factors affecting absorption include nebulizer efficiency, patient inhalation technique, and airway obstruction severity.

Distribution:
Following absorption, revefenacin demonstrates a moderate volume of distribution, indicating its distribution primarily to the lung tissues and limited peripheral penetration. Plasma protein binding is high, approximately 71% to 77%, predominantly to albumin and alpha-1 acid glycoprotein, which may influence its distribution kinetics. The drug's lipophilic nature supports its retention in pulmonary tissues, contributing to prolonged bronchodilator effects. In patients with COPD, distribution may be altered due to pathological changes in lung architecture.

Metabolism:
Revefenacin undergoes hydrolysis and subsequent metabolism primarily via non-cytochrome P450 enzymatic pathways to an active metabolite termed THRX-195518. This metabolite possesses similar anticholinergic properties but with lower potency compared to the parent compound. Metabolism occurs mainly in the lung and plasma, with minor hepatic involvement, predominantly via esterases. This targeting reduces potential drug-drug interactions mediated by cytochrome P450 enzymes and enhances safety, particularly in patients on polypharmacy.

Elimination:
The elimination of revefenacin and its metabolites occurs primarily through renal and biliary excretion. The parent drug has an elimination half-life ranging approximately 22 to 70 hours, enabling once-daily dosing convenience. Renal clearance accounts for a significant proportion of drug elimination, especially of metabolites. Fecal excretion via biliary pathways also contributes to drug removal. Patients with hepatic or renal impairment may exhibit altered elimination profiles; thus, clinical monitoring is advised in these populations. The long half-life supports its efficacy in maintenance therapy for COPD, ensuring sustained bronchodilation.

Dosage Forms

Available Dosage Forms:
Yupelri is supplied as a sterile inhalation solution designed specifically for nebulization.
- Single-use vials containing 175 mcg/3 mL of revefenacin inhalation solution.

Dosages for Adults and Adolescents:
- The standard recommended dose for maintenance treatment of COPD is one 175 mcg vial administered once daily via a nebulizer with a mouthpiece.
- The drug is indicated for adults 18 years and older; pediatric use is not approved.

Specific Patient Populations:
- No dosage adjustment is typically required for elderly patients; however, clinical monitoring is encouraged.
- Use with caution in patients with severe hepatic or renal impairment due to potential alterations in metabolism and elimination.
- Not recommended for patients under 18 years of age as safety and efficacy have not been established.
- Patients with glaucoma, prostatic hypertrophy, urinary retention, or bladder obstruction should use this drug cautiously due to anticholinergic effects.

Clinical guidelines recommend not mixing Yupelri with other nebulized medications during administration. The medication should be used immediately after opening the vial and stored at room temperature in its foil pouch until use.

Mechanism Of Action

Revefenacin, the active ingredient in Yupelri, acts as a long-acting muscarinic antagonist (LAMA), selectively blocking the M3 muscarinic receptors located on airway smooth muscle cells. By competitively inhibiting acetylcholine binding to these receptors, revefenacin prevents acetylcholine-induced bronchoconstriction. This leads to prolonged relaxation of the airway smooth muscle, thereby improving airflow and reducing COPD symptoms such as wheezing and shortness of breath.

At a cellular level, the blockade of M3 receptors inhibits the downstream signaling cascade involving the phospholipase C pathway, reducing the formation of inositol triphosphate (IP3) and subsequent intracellular calcium release. Decreased calcium availability prevents smooth muscle contraction, ultimately resulting in bronchodilation. Simultaneously, revefenacin shows minimal affinity for M2 receptors, which helps preserve negative feedback regulation of acetylcholine release, reducing side effects.

Biochemically, revefenacin's long-acting effect is attributable to its high receptor binding affinity and slow dissociation rate from M3 receptors. It forms a stable interaction that sustains muscarinic receptor blockade over 24 hours, ensuring once-daily dosing convenience. This pharmacodynamic profile is confirmed by clinical studies demonstrating significant improvements in lung function metrics such as forced expiratory volume in one second (FEV1) over extended periods.

Comparatively, revefenacin shares its mechanism with other anticholinergic bronchodilators like tiotropium but distinguishes itself by its nebulized formulation, enabling administration in patients with difficulty using handheld inhalers. This makes Yupelri a valuable option in maintenance therapy for patients with moderate to severe COPD, supported by robust clinical trials affirming its efficacy and safety for long-term use.

Pharmacological Actions

Long-acting muscarinic antagonist (LAMA) activity providing sustained bronchodilation.
Selective inhibition of airway smooth muscle M3 receptors to prevent bronchoconstriction.
Reduction in airway hyper-responsiveness and improved airflow in COPD patients.
Minimal systemic anticholinergic effects due to targeted pulmonary delivery.
Extended duration of action enabling once-daily dosing for patient convenience.
Inhibition of acetylcholine-induced intracellular calcium release.
Preservation of M2 autoreceptor function limiting reflex acetylcholine release.
Reduction of symptoms such as wheezing, cough, chest tightness, and dyspnea.
Improvement in pulmonary function tests including FEV1 and forced vital capacity.
Clinical benefit in maintenance therapy without role as a rescue medication.
Compatibility with standard jet nebulizer administration techniques.
Rapid onset of action typically within minutes post nebulization.
Demonstrated safety profile with low incidence of systemic side effects.
Active metabolite with similar but lower potency contributing to overall effect.
Limited impact on cytochrome P450 enzymes minimizes drug-drug interaction risk.

Therapeutic Or Clinical Uses

Maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.
Reduction of COPD symptoms such as dyspnea (shortness of breath), wheezing, and chronic cough.
Improvement of lung function parameters and quality of life in COPD patients.
Long-term bronchodilation to prevent airflow obstruction.
Management of moderate to severe COPD in adult patients.
Alternative for patients who have difficulty using handheld inhalers since it is nebulized.
Adjunct therapy in COPD patients requiring maintenance bronchodilation.
Prevention of bronchospasm in stable COPD patients.
Not indicated for acute bronchospasm or rescue treatment during COPD exacerbations.
Use in patients intolerant to other inhaled anticholinergics due to its nebulized form.
Potential benefit in patients with frequent exacerbations needing sustained airway relaxation.
Supports reduction in healthcare utilization by lowering exacerbation risks in maintenance care.
Therapy option compatible with other COPD treatments such as inhaled corticosteroids and beta-agonists.
Safe for long-term use with once-daily dosing compliance benefits.
Suitable for COPD patients with comorbidities requiring minimized systemic anticholinergic exposure.

Side Or Adverse Effects

Headache, reported as a common adverse effect.
Back pain, occurring in some patients receiving treatment.
Upper respiratory tract symptoms including runny nose, sneezing, cough, and sore throat.
Blurred vision or tunnel vision potentially related to anticholinergic effects.
Eye pain or redness and seeing halos around lights indicating possible glaucoma exacerbation.
Wheezing, choking, or breathing difficulties post inhalation requiring immediate medical attention.
Painful or difficult urination, or urinary retention symptoms especially in men with prostatic hypertrophy.
Allergic reactions such as hives, swelling of the face, lips, tongue or throat, and difficulty breathing rare but serious.
Possible nausea and vomiting reported in overdose situations.
Light-headedness and vision problems observed in overdose scenarios.
Dry mouth and throat irritation may occur due to anticholinergic properties.
Potential for urinary retention in susceptible individuals.
Minimal cardiovascular side effects due to limited systemic absorption.
No significant reports of tachycardia or arrhythmia in clinical use.
Localized irritation or bronchospasm risk if the nebulized solution is contaminated or improperly stored.

Precautions

Do not use if allergic to revefenacin or any component of the formulation.
Use caution in patients with narrow-angle glaucoma due to potential for increased intraocular pressure.
Monitor patients with prostatic hypertrophy or urinary retention for worsening symptoms.
Not indicated for treatment of acute bronchospasm; patients should have rescue inhalers available.
Inform doctor if pregnant or breastfeeding, as safety in these populations is not well established.
Elderly patients may require assessment for anticholinergic side effects and tolerability.
Avoid mixing Yupelri with other nebulized medications in the same reservoir.
Do not use if the inhalation solution changes color or appears cloudy, as this indicates compromise of drug integrity.
Store unopened vials in original foil pouch at room temperature, away from light and moisture.
Do not stop using Yupelri suddenly; abrupt discontinuation may exacerbate COPD symptoms.
Advise patients on proper nebulizer technique to ensure adequate drug delivery.
Patients with liver or kidney impairment require monitoring as elimination may be affected.
Use cautiously with other anticholinergic drugs to avoid additive side effects.
Inform healthcare providers of all concomitant medications to evaluate drug interactions.
Regular follow-up should assess lung function improvement and adverse effects.

Warnings

Yupelri is not a rescue medication for sudden or severe bronchospasm; use short-acting bronchodilators for acute attacks.
Seek immediate medical attention if COPD symptoms worsen rapidly or if medications appear less effective.
Potential risk of triggering acute narrow-angle glaucoma in susceptible individuals.
Use with caution in patients with significant prostatic hypertrophy or severe bladder obstruction.
Avoid use in pediatric patients under 18 years due to lack of established safety and efficacy.
Discontinue use if signs of hypersensitivity or severe allergic reaction develop.
Careful monitoring is warranted in patients with pre-existing cardiac conditions despite low systemic absorption.
Avoid exposure to contaminated nebulizers to prevent bronchospastic reactions.
Not recommended during pregnancy unless potential benefits outweigh risks as animal studies are insufficient.
In case of overdose, seek emergency help immediately due to risk of anticholinergic toxicity.
Ensure patients understand that Yupelri provides maintenance control but does not relieve sudden airway constriction.
Patients should report any vision changes or urinary difficulties promptly.
Proper storage is essential to maintain drug stability and effectiveness.
Concomitant use of other antimuscarinic drugs may increase risk of adverse effects.

Contraindication

Known hypersensitivity or allergy to revefenacin or any component of the inhalation solution.
Hypersensitivity to other anticholinergic drugs similar in chemical structure.
Patients with severe hypersensitivity reactions to latex, if vial components contain latex (check packaging).
Use contraindicated in pediatric patients younger than 18 years due to lack of safety data.
Patients with untreated narrow-angle glaucoma where the risk of intraocular pressure increase outweighs benefit.
Severe urinary retention or bladder neck obstruction where anticholinergic effects may exacerbate condition.
Hypersensitivity to nebulizer components or exposure to contaminated nebulizer causing bronchospasm.
Contraindicated in acute bronchospasm requiring immediate relief, as the drug is maintenance only.
Patients with known severe hepatic impairment when cautious use is advised due to altered metabolism.
History of severe allergic reaction to similar anticholinergic bronchodilator medications.

Drug Interactions

Concurrent use with other anticholinergic agents may enhance antimuscarinic side effects such as dry mouth, urinary retention, and constipation.
Use caution when combining Yupelri with medications for glaucoma due to potential additive effects on intraocular pressure.
Interactions may occur with drugs used to treat depression, anxiety, or mood disorders, potentially increasing anticholinergic load.
Medications for Parkinson’s disease, which have anticholinergic effects, can interact to increase side effect risk.
Cold or allergy medications containing anticholinergic properties may potentiate adverse reactions.
Drugs used to treat overactive bladder may have additive effects, requiring clinical monitoring.
Concomitant use with bronchodilator asthma medications necessitates monitoring for cardiovascular or anticholinergic side effects.
Potential pharmacokinetic interactions with substances affecting plasma esterases metabolism are minimal but possible.
Revefenacin has low cytochrome P450 interaction potential, making significant interactions less common.
Patients should disclose use of all over-the-counter medications, vitamins, or herbal supplements to healthcare providers.
Interactions with medications leading to urinary retention or glaucoma exacerbation require careful assessment.
No significant interactions reported with commonly used inhaled corticosteroids or beta-2 agonists.
Combination with sedatives or alcohol may increase risk of sedation or dizziness.
Monitoring is recommended when starting or stopping concomitant medications with anticholinergic properties.
Inhalation route reduces systemic interactions but clinical vigilance remains essential.

Preparations Of The Drug

Yupelri is supplied as a sterile inhalation solution for nebulization in single-use vials.
Each vial contains 175 mcg of revefenacin in 3 mL of aqueous solution.
Vials are individually sealed in foil pouches to maintain stability and protect from light and moisture.
Supplied in cartons containing multiple vials for daily dosing convenience.
No additives requiring mixing; the solution is ready for immediate use upon opening.
Intended for use with standard jet nebulizer systems equipped with a mouthpiece or face mask.
Not compatible for mixing with other nebulized medications in the same reservoir during administration.
Storage instructions specify room temperature storage (20°C to 25°C), protected from freezing and light.
Dispose of any opened vial immediately after use to prevent microbial contamination.
Packaged according to regulatory standards ensuring sterility, labeling, and traceability.
Available through prescription only, with specific patient education materials provided.
Manufacturer ensures batch consistency with stringent quality control measures.
Vial design facilitates easy handling for patients with limited dexterity.
Complementary patient instructions available for nebulizer use, storage, and disposal.
Packaging includes child-resistant features where applicable to enhance safety.